All News
Belimumab’s Sustained Impact in Lupus
In the wake of the EULAR 2023 guidelines on the management of SLE, it is perhaps pertinent that the EULAR 2024 congress features three abstracts from a large integrated analysis from five international Phase 3 belimumab trials in adults with active SLE (BLISS-76, BLISS-52, North East Asia, EMBRACE and BLISS-SC). Participants were randomised to belimumab (10 mg/kg/month intravenously or 200 mg/week subcutaneously) or placebo, plus standard therapy.
Read Article
#SARD #ILD
Who to screen for #rheumatic #diseases
For
ILD
#ACR guidelines
Screening May also depend on ILD prevalence
Not sure if frequency of screening and how to screen
@jeffsparks #ORA24 @ORAexec https://t.co/BcyyYLKvr6
Links:
Janet Pope Janetbirdope ( View Tweet)
The original direct comparison study! https://t.co/hqrPKfNW1y
Bella Mehta bella_mehta ( View Tweet)
SLE RPI may be used more frequently
and can connect the digital dots! @RheumNow https://t.co/UdVIyZJhJV
Bella Mehta bella_mehta ( View Tweet)
#EULAR2024 OP0077 Please find an interview with my dear colleague @edvital on the importance of achieving and sustaining B cell depletion for improved clinical response in #lupus #SLE @RheumNow
https://t.co/4rTtFWxSvs https://t.co/4esoFTsgzC
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0124 EULAR recommended target oral Pred =<5mg/d. Should the threshold of LLDAS be changed to LLDAS5? Multicentre study showed the protection gained from mortality, irreversible organ damage accrual and flare was no different btw the two targets @RheumNow #EULARBEST https://t.co/GbP25tTmX8
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0145 Can we reclassify people with ANA+ RMD to improve clinical outcomes & stratify for basket trials? Deep machine learning identified distinct classes of ANA-RMD with distinct phenotypes & predicted long-term outcomes better than the legacy diagnoses @RheumNow https://t.co/W2hmmj0v8Y
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0149 When the Doctor says YES but the patients say NO. Data from UK BILAG-BR in moderate to severe #lupus showed ~half patients who met clinical response did not improve their psychological wellbeing. Factors of discordant: ancestry, damage, SLEDAI-2K @RheumNow https://t.co/9cqcPripA2
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0180 Can we safely taper GC in #lupus patients who are in remission? Single study in Italy showed in pts with SLEDAI=0 + pred =<5mg/d + stable IS/HCQ, GC discontinuation after proper tapering appeared safe and was associated with a low risk of flare @RheumNow https://t.co/8IIgPuZUrF
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0187 Can we identify a subgroup of #lupus patients at the outset who may benefit from early intensive therapies inc biologics? Data from an inception cohort showed low complement & cSLEDAI=>9 were assoc w increased risk of intensive therapy need/Tx failure @RheumNow https://t.co/jmahjcqom3
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
A fantastic tool LupusGPT by @LupusEurope for our patients to help self-manage #SLE was launched yesterday. Building on information from Lupus100 & supplemented by scientific data and relevant guidelines. I have tried it and worked well. Please disseminate https://t.co/a1qXGZyRE6 https://t.co/LTQM6A8Zq3
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0206 In a cohort study, of pts with #lupus nephritis, 81% tapered IS ~32 mths post-renal response. Of this, 17% flared. Strategies for safe tapering: ensure CR is achieved, low SLEDAI-2K at 12mths, low SLEDAI-2K & on HCQ at the time of tapering initiation @RheumNow https://t.co/hAMAdsL7Jn
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 POS0152 How prevalent is severe refractory #lupus? Multicentre cohort in Asia defined this as SLEDAI-2K=>10 + on GC + immunosuppressant. One in 7 met this definition, assoc w high activity & low T2T achievement. Useful for sample size calc for clinical study @RheumNow https://t.co/bq4gxX7kjI
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 POS0191 Development and validation of plasma biomarkers to predict #lupus flare in the next 12 weeks. Quick turnover results. Need to focus on steps to bring these novel tools from bench to clinical practice @RheumNow https://t.co/64EppGI7bv
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0089 Promising data from Phase 2 RCT on dual blockade depletion & BAFF-R-i, Ianalumab in #lupus. After 24 wks double-blind, sustained response (SRI-4 + Pred ≤5mg/d or ≤ BL dose) was seen in IAN-IAN group while PBO-IAN improved in open label phase at 48wks @RheumNow https://t.co/MUo76ii4vB
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0059 Propensity match scoring of 179 pts w #lupus nephritis in AURA & AURORA1 vs ALMS. Triple therapy (voclosporin + MMF2g/d + low dose GC) led to earlier, greater reduction in proteinuria, & improved safety profile vs dual (MMF3g/d or Cyclo + High dose GC) @RheumNow https://t.co/UdcuaRTtzC
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0017 If one target isn’t enough, why not two! Open label Phase I showed a double-pronged approach, compound BCMA-CD19 CAR Tcells (cCAR) improved clinical response, autoabs elimination & minimal infection in severe refractory #lupus nephritis @RheumNow #EULARBEST https://t.co/6MPHZKxKTB
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Can you ⬇️
#Glucocorticoids or #immunesuppressive in #SLE & change am’t of damage
From Asia Pacific #lupus collab
(Biologics not included)
Compared 7.5 mg #prednisone or less
Or DMARD
1/2 flared after LLDAS
⬇️dose didn’t prevent damage
#EULAR2024
@eular_org @RheumNow https://t.co/QmjEz87Cvw
Janet Pope Janetbirdope ( View Tweet)
#EULAR2024 Cutaneous #lupus is variable & can be difficult to treat. Promising post-hoc data frm Phase 2 RCT showing Deucravacitinib (Tyk2-i) led to improvement & sustained CLASI-50 response in all subtypes (ACLE, SCLE, Chonic and Discoid) @RheumNow #EULARBEST https://t.co/ArAzdLYiYY
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
